Manufacturing

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

While allogeneic therapies can use existing regulatory and quality frameworks, autologous treatments will require pharma’s adoption of true just-in-time and right-first-time concepts, says consultant James Blackwell.


Reinterpreting Benchmarks for Innovative Therapies

Mustang intends to combine an oncolytic virus with an interleukin-13 Rα2-(IL13Rα2)-specific chimeric antigen receptor to potentially enhance efficacy in treating glioblastoma multiforme.

Mustang Bio, Nationwide Children’s Hospital Sign License Agreement for Oncolytic Virus Therapy

The company will invest an additional $60 million to expand its manufacturing facility in Durham County, NC.

Novartis’ AveXis to Expand Gene Therapy Manufacturing in North Carolina

The partnership will expand Lonza’s offering of hematopoietic cell lines.

Lonza, AllCells Partner on Hematopoietic Primary Cells

The acquisition will boost Hitachi Chemical’s presence in the European regenerative medicines market.

Hitachi Chemical to Acquire apceth Biopharma

Janssen and MeiraGTx will collaborate on the development and commercialization of gene therapies for treating inherited retinal diseases.

Janssen, MeiraGTx Partner on Eye-Focused Gene Therapy

TC BioPharm (TCB), developer of CAR-T immuno-oncology products, has completed its first allogenic Gamma Delta T (GDT) cell banks.


First Allogenic Cell Banks for CAR-T Cancer Therapy Products Created

G-CON will provide a complete cleanroom infrastructure for GE Healthcare’s cell therapy and viral vector production platforms that will simplify early-stage manufacturing efforts.

G-CON Manufacturing and GE Healthcare Collaborate to Advance Early-Stage Cell Therapy and Viral Vector Manufacturing

Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe

Locate Bio to be Granted Key US and EU Patents for its Gene Delivery Tech

Agenus will leverage Selexis’ SUREtechnology Platform to progress Agenus’ portfolio of next-generation antibody programs.

Manufacturing, Cell Therapies